- Home
- NEWS
- REGIONAL
- THIS WEEK'S PAPER
- BLOGS
- Multimedia
- OPINION
- A&E
- LISTS
- PEOPLE
- EVENTS
- Classifieds
- Subscribe
Life Science & Biotech
Brain barrier breached in push to deliver Alzheimer's drug
May 25, 2011
Scientists with Roche Holding AG, the parent company of Indianapolis-based Roche Diagnostics Corp., may have found a way to
overcome a blood barrier that keeps drugs from directly entering the brain, potentially opening new pathways to attack Alzheimer’s
disease.
MoreLilly licenses Xigris rights to new biotech firm
May 23, 2011
J.K. WallEli Lilly and Co. has agreed to license the U.S. marketing rights of its slow-selling sepsis drug Xigris to a newly created
local biotech company called BioCritica that will seek to reinvigorate sales of the medication.
MoreZimmer faces new threat to dominance
May 16, 2011
J.K. WallWarsaw-based Zimmer Holdings Inc. has enjoyed eight years as the giant in the industry of selling knee- and hip-replacement
implants to hospitals. But now it faces a challenge from Johnson & Johnson.
MoreBISHOP: Warsaw's orthopedics whizzes will master biologics
May 14, 2011
Industry cluster in northern Indiana has adapted to every other change in health care, and will absorb tissue regeneration,
too.
MoreEndocyte's potential enthralls investors
May 7, 2011
Chris O'MalleyShares of Endocyte Inc. have doubled since the company’s initial public offering in February—even though the common
wisdom is it won’t see sales from its first cancer drug until 2014.
MoreIndianapolis bio sector hopeful as venture firms cash out
April 30, 2011
Chris O'MalleyProfits flowing from earlier investments could mean more available capital, but firms continue to be selective in placing
their bets.
MoreDow AgroSciences reports record revenue
April 28, 2011
IBJ StaffIndianapolis-based Dow AgroSciences on Thursday reported sales of $1.6 billion in its first quarter, up 17 percent from the
same period last year due to higher volume and increased prices.
MoreLife sciences firm Hycor moving HQ, jobs to central Indiana
April 27, 2011
IBJ StaffCalifornia-based Hycor Biomedical Inc. plans to move its headquarters to central Indiana, creating as many as 20 jobs in the
next two years, state economic development officials announced Wednesday morning.
MoreRoche wins approval of HPV test
April 25, 2011
J.K. WallRoche Diagnostics Corp. won regulatory approval for a new HPV test, giving it a technological edge in the $300 million market
for automated cervical cancer tests.
MoreMuch unknown about new Cook Group CEO
April 22, 2011
Scott OlsonCarl Cook has been tabbed to replace his father, Bill Cook, who died a week ago. But many in the Bloomington business community
know little about him, which reflects the company's strict privacy policy.
MoreFDA wants further testing of Lilly pancreas drug
April 16, 2011
Associated PressEli Lilly and Co. Inc. said Friday that the FDA has asked the drugmaker to conduct another clinical trial of its proposed
pancreas drug before it resubmits an application to have the drug approved for sale.
MoreBill Cook, medical device magnate and philanthropist, dies at 80
April 15, 2011
IBJ Staff and Associated PressThe founder of Bloomington-based life sciences giant Cook Group Inc. and the wealthiest man in Indiana leaves a legacy of
dozens of historic structures saved from decay or demolition. He also was a major donor to Indiana University and its athletics
department.
MoreLilly’s Bydureon wins backing of European drug panel
April 15, 2011
Bloomberg NewsThe drug awaits final action by the European Commission, which has the authority to approve medicines for the European Union.
The Commission usually makes a decision on CHMP recommendations within two to three months.
MoreChina making big gains in drug R&D jobs state covets
April 9, 2011
Greg AndrewsThe total annual cost for one researcher at Lilly might run $300,000 to $350,000 a year. The figure at Crown Bioscience is
one-third of that, said a company executive.
MoreWishard gives IT firms in health and life sciences a place to test products
April 9, 2011
Chris O'MalleyTechPoint-led initiative is meant to help bring inventions to market by giving them a trial in real-world setting.
MoreTax breaks approved for bioanalytical lab operator
April 7, 2011
The Metropolitan Development Commission on Wednesday preliminarily approved Advion BioServices Inc.'s request for a tax abatement
to build a laboratory at Purdue Research Park in Indianapolis.
MoreBioanalytical researcher seeking abatement for new lab
April 5, 2011
Scott OlsonAdvion, a provider of bioanalytical research and a subsidiary of Ithaca, N.Y.-based Advion BioSciences Inc., is expected to
open the 22,000-square-foot lab in mid-May with 49 employees, according to the company's application.
MoreIndiana college to break ground on pharmacy school
April 1, 2011
IBJ Staff and Associated PressNorthern Indiana's Manchester College plans to begin work this summer on the college's new $18 million pharmacy school.
MoreScientists question claims in biotech letter
April 1, 2011
Associated PressThe widespread Internet posting of a letter by a retired Purdue University researcher who says he has linked genetically modified
corn and soybeans to crop diseases and to abortions and infertility in livestock has raised concern among scientists that
the public will believe his unsupported claim is true.
MoreZimmer goes on offensive against lawyers
March 30, 2011
J.K. WallThe Warsaw-based maker of orthopedic implants has filed suit to stop a Detroit-area law firm from making allegedly false claims
and using its trademarks on websites designed to attract plaintiffs to sue Zimmer over one of its knee-replacement implants
called NexGen.
MoreMarcadia Biotech principals ponder next course
March 22, 2011
Chris O'MalleyMarcadia execs French, Hawryluk reflect on massive growth of Carmel firm after sale to Roche.
MoreDrugmakers call off animal-health deal, possible asset sale
March 22, 2011
IBJ Staff and Bloomberg NewsDrugmakers Merck & Co. and Sanofi-Aventis SA have abandoned plans to combine their animal-health businesses after wrestling
with regulators for a year over potential divestitures.
Indianapolis-based Eli Lilly and Co. was among a list of possible suitors for about $1 billion in assets the two companies
considered selling.
MoreResearch jobs could flow from Purdue quad
March 19, 2011
Marc D. AllanPurdue University officials and others connected with the life sciences in Indiana say the planned $164 million Life and Health
Sciences Quadrangle at the West Lafayette campus will mean high-paying jobs, retention of highly skilled scientists, and researchers
who might well have left the state for either coast.
MoreDow Agro thinks it has a winner
March 16, 2011
J.K. WallThe Indianapolis-based company released more details this month about its Enlist Weed Control System, which would genetically
modify corn, soybeans and cotton to be resistant to one of the most common weedkillers.
MoreLilly agrees to buy European animal health company
March 14, 2011
J.K. WallElanco, the animal health division of Eli Lilly and Co., has agreed to acquire Jannsen Animal Health, a subsidiary of New
Jersey-based Johnson & Johnson, pending regulatory approval. Financial terms of the deal were not disclosed.
More
Sponsored by
ADVERTISEMENT
on Facebook & Twitter
on Facebook & Twitter
 Follow IBJ's Tweets on these topics: |
||
| @IBJNews | @Propertylines | @IBJTheScore |
| @IBJArts | @IBJHealthcare | @IBJDining |
| @IBJLists | @IBJSmallbiz | |
ADVERTISEMENT
Back to TopCopyright © All Rights Reserved. Privacy Policy | Terms of Use.
Design, CMS, Hosting & Web Development :: ePublishing.
Additional Hosting & Delivery by
First, the Athenaeum is going to have to get past the hurdle with the Lockerbie residents and the agreement that the parcel would be residential. Second, and in my opinion, this prime piece of property should include parking, PLUS, a black box theater(s), some market rate and affordable artist housing and a plan to renovate and reconfigure the second story theater. I would negotiate to add the DeHaan property surface parking lot into the development mix, place a one story surface parking garage on the DeHaan lot on the street level (for the Dehaan tenants use during the daytime) and add a second story to the garage that would become an addition to the current second story theater and then change the direction of the theater by moving the stage across the alley and on top of the DeHaan lot parking. You can add all the stage elements that are currently missing from the Athenaeum stage to make it more attractive for use by Ballet, Opera and traveling productions. Plus, the theater changes would probably help solve some of the soundproofing issues. Alas,it does not seem to be a part of the strategic plan to conduct a study to determine best use of the property. Seems like the current plan is a quick and easy move that ignores the property best use/potential and any strategic property planning for the effect on future generations.
I recall that MSA's pilings are still in the ground and hard to remove. It’s not likely any proposal will include significant underground construction/parking because of this. Start adding 2 floors of retail, 8 floors of parking and 5-10 floors of possible hotel, and/or 10-20 floors of residential, and you are at 30 floors already with possible expansion of all the uses. But then again I could be wrong.
Accoriding to their website there is no deadline to the Do Not Call list. What is this article referring to??
On what planet are they entitled to this largesse from the stockholders? These people make multi-million dollar salaries: Pay for your own personal travel.
It matters because they're already paid enormously fat salaries: Pay for your own personal travel. Being "taxed on it" isn't a valid excuse--so what? They're still being gifted a raft of luxury perks from somebody else's money on top of an enormous, lavish salary.